history of glp-1 drugs Continued growth for receptor agonists and SGLT-2 inhibitors in 2017 The discovery and development of
Description
When will drugs like retatrutide, CagriSema, and orforglipron be available
Suppressed macrophage infiltration followed by reduced macrophage foam cell formation by active forms of GLP-1 and GIP was demonstrated by Nagashima M, et al
Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes
Villaschi A, Ferrante G, Cannata F, Pini D, Pagnesi M, Corrada E, Reimers B, Mehran R, Federici M, Savarese G et al
